Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop and Commercialize Biosimilars

 Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop and Commercialize Biosimilars

Waters Launches Peptide Multi-Attribute Method for BioAccord System to Develop and Commercialize Biosimilars

Shots:

  • The new peptide MAM workflow for the BioAccord LC-MS system that helps to monitor critical quality attributes of protein-based drugs that can affect the safety & efficacy of innovator drugs and biosimilars
  • By integrating BioAccord system on the waters_connect platform, scientists have a sensitive multiplexed method to accurately assess the attributes of protein-based drugs that enable rapid decision-making for product development, manufacturing, and release. The system also monitors product variants, degradation and impurities, and process stability
  • The BioAccord system combines the ACQUITY UPLC I-Class and ACQUITY RDa mass detector featuring SmartMS enabled usability features

Click here to­ read full press release/ article | Ref: Businesswire | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post